• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure gains on additional Optune data

April 17, 2017 By Brad Perriello

Novocure touts new Optune dataShares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma.

Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication.

The Jersey, U.K.-based company said a post-hoc analysis of the EF-14 study showed that a median overall survival rate for Optune-treated patients in combination with physician’s best-choice 2nd-line chemotherapy rose by 28%, compared to best-choice 2nd-line alone from 9.2 months to 11.8 months. Bevacizumab was the most-chosen 2nd-line treatment for both arms, Novocure said; the data showed that median overall survival for the Optune-bevacizumab group rose 31% compared with the control arm over the same period.

Earlier this month, Novocure shares jumped nearly 50% on 5-year data from the EF-14 trial. Data from 695 patients showed a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, the company said.

“Taken in conjunction with the previously reported benefits with TTFields for newly diagnosed GBM in the EF-14 interim analysis, these results support the early initiation and continued use of Optune in combination with standard systemic therapies for the treatment of GBM,” trial investigator Dr. Santosh Kesari, of Santa Monica, Calif.’s Pacific Neuroscience Institute, said in prepared remarks. “The publication of these data adds to the growing body of evidence around Optune’s efficacy and supports the incorporation of Optune as a combination treatment for patients with glioblastoma.”

NVCR shares were up 4.3% to $10.90 apiece today in mid-morning trading.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Radiosurgery, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS